ISOBE et al.

Atty. Dkt.: Q86915

Preliminary Amendment

Page 2

AMENDMENTS TO THE SPECIFICATION

Please delete the present Abstract of the Disclosure.

Please add the following new Abstract of the Disclosure:

There are provided a uracil derivative represented by the general formula (I):

$$\begin{array}{c|c}
O & X \\
 & X \\
 & R^2 \\
 & N \\
 & R^3 \\
 & Ar & R^4
\end{array}$$
(I)

or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for the treatment of, in particular, allergic diseases in which a type IV allergic reaction participates, which comprises the above-mentioned uracil derivative or pharmaceutically acceptable salt thereof as an active ingredient, that is, there are provided a novel compound useful for treating various allergic diseases, in particular, diseases in which a type IV allergic reaction participates, and a pharmaceutical composition for the treatment of allergic diseases comprising this compound as an active ingredient.